BioLineRx (NASDAQ:BLRX) and Genmab A/S (NASDAQ:GMAB) Head-To-Head Analysis

Genmab A/S (NASDAQ:GMAB) and BioLineRx (NASDAQ:BLRX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Genmab A/S and BioLineRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0	3	9	1	2.85
BioLineRx	1	0	0	0	1.00

Genmab A/S presently has a consensus target price of $43.39, indicating a potential downside of 0.92%. Given Genmab A/S’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Genmab A/S is more favorable than BioLineRx.

Institutional & Insider Ownership

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Genmab A/S has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.

Profitability

This table compares Genmab A/S and BioLineRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
BioLineRx	-502.08%	-34.80%	-18.27%

Earnings & Valuation

This table compares Genmab A/S and BioLineRx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72 billion	7.35	$963.00 million	$1.27	34.48
BioLineRx	$1.18 million	8.61	-$1.17 million	($1.69)	-1.21

Genmab A/S has higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Genmab A/S beats BioLineRx on 13 of the 15 factors compared between the two stocks.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.